The Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, NL-1066 CX Amsterdam, The Netherlands.
Eur J Surg Oncol. 2012 Jan;38(1):25-30. doi: 10.1016/j.ejso.2011.09.005. Epub 2011 Oct 2.
Neoadjuvant chemotherapy is gaining acceptance as an option for breast cancer treatment, particularly in young women. These women may seek immediate breast reconstruction after mastectomy even though it is not known whether such preoperative chemotherapy may be detrimental to post-reconstruction wound healing. Therefore, we set out to assess the influence of neoadjuvant chemotherapy for invasive breast cancer on the short-term complications after skin sparing mastectomy and immediate prosthetic reconstruction.
The short-term surgical outcome of 48 immediate breast reconstructions in 37 women treated with neoadjuvant chemotherapy from 2006 through 2009 was prospectively compared to that of 215 immediate reconstructions in 176 women who were operated in the same period without neoadjuvant chemotherapy.
The overall rate of short-term postoperative complications was significantly less among neoadjuvantly treated women (15% vs. 29%; p = 0.042) but this did not result in a reduction of loss of prostheses (8% vs. 11%; p = 0.566).
Because neoadjuvant chemotherapy is not associated with an increase in short-term complications after skin sparing mastectomy and immediate prosthetic reconstruction in patients with invasive breast cancer, such combined surgical therapy may be offered as treatment option for this particular group of patients also.
新辅助化疗作为乳腺癌治疗的一种选择越来越被接受，尤其是在年轻女性中。这些女性可能会在乳房切除术后立即寻求乳房重建，尽管目前尚不清楚术前化疗是否会对重建后的伤口愈合有害。因此，我们着手评估新辅助化疗对保留皮肤的乳房切除术和即刻假体重建后短期并发症的影响。
前瞻性比较 2006 年至 2009 年间接受新辅助化疗的 37 例女性的 48 例即刻乳房重建的短期手术结果与同期无新辅助化疗的 176 例女性的 215 例即刻重建。
新辅助治疗组的短期术后并发症总体发生率明显较低（15%对 29%；p=0.042），但这并未导致假体丢失减少（8%对 11%；p=0.566）。
由于新辅助化疗与保留皮肤的乳房切除术和即刻假体重建后短期并发症的增加无关，因此对于患有浸润性乳腺癌的患者，这种联合手术治疗也可以作为一种治疗选择。
